Anti-tumor necrosis factor therapy: The Australian experience

Nash, P. (2006) Anti-tumor necrosis factor therapy: The Australian experience. APLAR Journal of Rheumatology, 9 2: 119-126. doi:10.1111/j.1479-8077.2006.197_1.x

Author Nash, P.
Title Anti-tumor necrosis factor therapy: The Australian experience
Journal name APLAR Journal of Rheumatology   Check publisher's open access policy
ISSN 0219-0494
Publication date 2006
Sub-type Article (original research)
DOI 10.1111/j.1479-8077.2006.197_1.x
Volume 9
Issue 2
Start page 119
End page 126
Total pages 8
Editor C. S. Lau
Place of publication Carlton South, VIC, Australia
Publisher Blackwell-Wiley
Collection year 2006
Subject C1
321028 Rheumatology and Arthritis
730114 Skeletal system and disorders (incl. arthritis)
Abstract Anti-tumor necrosis factor (TNF) therapy for the management of rheumatic diseases has been reimbursed in Australia progressively per agent and disease indication since 2003. Initial projections of uptake were grossly overestimated. In this article the anti-TNF experience in Australia is reviewed, including results of an eligibility study, Australian Rheumatology Association guidelines, anti-TNF registry, and a report of adverse effects. These observations may assist APLAR countries currently coming to terms with anti-TNF drug registration and funding.
Keyword Adverse effects
Anti-TNF agents
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2007 Higher Education Research Data Collection
School of Medicine Publications
Version Filter Type
Citation counts: Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 10:43:43 EST